The AHSN Network has supported many innovators to help advance our health and care system. Find out more about successful innovations supported by the NHS.
Find your nearest AHSN
Rehabilitation EnAblement in CHronic Heart Failure (REACH-HF)
REACH-HF (Rehabilitation EnAblement in CHronic Heart Failure) is a facilitated evidence based cardiac rehabilitation (CR) and self-management programme for use at home. It comprises the ‘Heart Failure Manual’, a Relaxation CD, a choice of exercise (walking programme or a chair-based DVD) a ‘Progress Tracker’ for patients, and a ‘Family and Friends Resource’ for caregivers.
MetaGuideX receive £50,000 investment through Oxford AHSN Accelerator programme
The Oxford AHSN Accelerator programme, in collaboration with BioCity and regional partners from the NHS, industry and research within the Thames Valley, offers a launchpad for entrepreneurs and their ventures to move from idea to market. MetaGuideX won a place on the intensive eight-week programme and pitched to investors on the final day of the Accelerator programme in November 2020.
Johnson & Johnson and Oxford AHSN cement relationship over five-year strategic partnership
The Oxford AHSN already enjoys a very productive relationship with the global healthcare company Johnson & Johnson (J&J). J&J is one of the largest employers linked to healthcare in our region with its headquarters in High Wycombe.
Qiagen/ APIS Assay Technologies partnership
Qiagen, a molecular diagnostics company, and spinoff company APIS Assay Technologies, the AHSN, academia and the NHS have created a long-term partnership that has brought investment and jobs to the Greater Manchester area. Access to new tests and targeted treatments developed through pioneering research will bring fast-tracked real health benefits to local residents, and ultimately people nationally and internationally.
Oxford AHSN develops the business case for cobas® Liat® influenza test and wins Near Patient Testing award at the UK Diagnostics Summit
The cobas® Liat® System is a fast, easy-to-use, compact PCR system designed for on-demand testing in point-of-care settings such as clinics, pharmacies, and hospital and satellite laboratories. The Oxford AHSN assisted in the first UK based evaluation of the the cobas® Liat® Influenza A/B test, in the Emergency Department (ED) of the Royal Berkshire Hospital, which provides secondary emergency care for most of Berkshire. The test is a PCR based test using either nasopharyngeal or throat swabs and requires minimal sample preparation. The evaluation aimed to see if the test reduced patient length of stay, reduced antibiotic use and increased the use of antivirals. The Oxford AHSN project managed the evaluation and provided active, hands-on support. The Oxford AHSN also enlisted York Health Economics Consortium (YHEC) to provide impartial health economics, using the metrics collected during the evaluation and anonymised data. The health economic data was then used to inform the business case for the Trust procuring the tests going forward. Plans to roll out the test in community settings have been put on hold pending a product update to include a Covid-19 test.
Smart with your heart
Smart with your Heart aims to reduce readmissions in heart failure pathways by using digital technology. The aim was to reduce the 'revolving readmission door' for heart failure patients, by working in partnership with secondary and primary care settings and 3 digital providers.
Thousands more pregnant women benefit from test to rule out pre-eclampsia following national rollout led by AHSNs
Quick, accurate blood tests which can help rule out pre-eclampsia are improving care for pregnant women and their unborn babies, reducing anxiety and saving the NHS money. AHSNs are leading a rapid adoption project for these tests into maternity units across the country.
Quicker stroke care and reduced costs
New artificial intelligence (AI)-driven imaging support software which has the potential to deliver huge benefits to hundreds of stroke patients each year and significant cost savings to the NHS has been implemented at the Royal Berkshire NHS Foundation Trust (RBH). The Oxford AHSN is supporting wider regional roll-out backed by NHS England. The CE-marked e-Stroke Suite developed by Brainomix Ltd includes tools for non-contrast CT and CT angiography brain scans, connecting physicians and facilitating information transfer. The software supports physicians in identifying patients who would benefit from acute stroke treatments, selecting patients most likely to benefit from specific interventions, such as mechanical thrombectomy.
Consortium including Oxford AHSN and POCKiT Diagnostics secures over £700,000 in grant funding to improve diagnosis of stroke within the NHS in England
Stroke affects 100,000 people in the UK each year . 33% of patients will die and 90% of survivors will have a disability for the rest of their lives.
PAD and PAWS: Peripheral Arterial Disease and Prevention, Assessment, Wound management, Self-care
This service improvement programme aims to enable primary care staff to improve lower limb vascular assessments in patients with leg ulcers to allow appropriate treatment to start earlier.
Gendius developed product Intellin® is an intelligent diabetes management platform that uses clinical data to predict the trajectory of an individual's diabetes and helps to mitigate progression through smart tips. Powered by sophisticated AI algorithms, Intellin® is changing the way diabetes is managed. The Intellin® App is today the fastest downloaded diabetes app in the world.